ID
45518
Descripción
Principal Investigator: Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA MeSH: Waldenstrom Macroglobulinemia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000740 Whole genome sequencing was conducted on 10 tumor/germline paired samples along with 20 additional unpaired tumor samples from patients with Waldesntrom's macroglobulinemia. Tumor lymphoplasmacytic lymphoma cells were obtained from CD19+ selected bone marrow mononuclear cells. Germline tissue was obtained from CD19 depleted peripheral blood mononuclear cells. High molecular weight DNA was then submitted for whole genome sequencing with Complete Genomics and aligned to HG19/NCBI human reference build 37.
Link
Palabras clave
Versiones (1)
- 14/12/22 14/12/22 - Chiara Middel
Titular de derechos de autor
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA
Subido en
14 de diciembre de 2022
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000740 Whole Genome Sequencing of Waldenstrom's Macroglobulinemia
Subject ID, consent group, subject source, source subject ID, and affection status of participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- Subject ID, sample ID, sample source, sample source ID, and sample use variable associated with participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of sample, and sequencing center variable associated with participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- Subject ID, sex, and paired germ line sample control of participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
Similar models
Subject ID, consent group, subject source, source subject ID, and affection status of participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- Subject ID, sample ID, sample source, sample source ID, and sample use variable associated with participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of sample, and sequencing center variable associated with participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
- Subject ID, sex, and paired germ line sample control of participants with or without Waldesntrom macroglobulinemia and involved in the "Whole Genome Sequencing of Waldenstrom's Macroblulinemia".
C0441833 (UMLS CUI [1,2])
C0242481 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])
Sin comentarios